Fig. 1From: Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapyPET CT Imaging of Patient Undergoing Combination Ipilimumab/Nivolumab Immunotherapy. a left arrow, mesenteric lesion. right arrow, left upper extremity cutaneous lesion (1) prior to initiating combination ipilimumab/nivolumab therapy, (2) following the second dose of combination ipilimumab/nivolumab therapy. b (1) prior to initiating combination ipilimumab/nivolumab therapy, (2) following the second dose of combination ipilimumab/nivolumab therapy, (3) 1Â year following the third dose of combination ipilimumab/nivolumab therapy and treatment discontinuation due to toxicityBack to article page